Survival in Immune Checkpoint Inhibitor–Treated Patients With Rheumatoid Arthritis and Non–Small Cell Lung Cancer: An Observational Cohort Study
Arthritis Care & Research · 2025
DOI: 10.1002/acr.25561 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Arthritis Care & Research, 2025. Verfasst von Deanna P Jannat-Khah und 4 weiteren Autor:innen. Beteiligte Einrichtung: Hospital for Special Surgery, New York, New York. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Immune Checkpoint Inhibitors, Arthritis, Rheumatoid, Lung Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAMS NIH HHS, Hospital for Special Surgery, National Institute of Arthritis and Musculoskeletal and Skin Diseases.
Abstract (Originalsprache)
Objective
We aimed to compare overall survival (OS) in immune checkpoint inhibitor (ICI)–treated patients with metastatic non–small cell lung cancer (mNSCLC) with pre‐existing rheumatoid arthritis (RA) versus those without RA.
Methods
A retrospective cohort study using Medicare claims data was performed. Participants included patients aged ≥66 years with a diagnosis of a malignant neoplasm of lung and bronchus who initiated nivolumab, pembrolizumab, or atezolizumab between March 4, 2015 and April 11, 2019, which is after the US Food and Drug Administration (FDA) approval of ICIs for mNSCLC but before the first FDA approval for stage III disease. Survival analysis using Kaplan‐Meier and adjusted Cox proportional hazard models was performed.
Results
A total of 2,732 people with mNSCLC (N = 790 RA and N = 1,942 non‐RA) were in the analytic cohort. Patients with RA were more likely to be female and had more comorbidities than patients without RA. Patients with RA were more likely to be taking steroids than those without RA (63% vs 45%) but equally likely to be taking dexamethasone, usually prescribed for cancer palliation, specifically (27% vs 28%) before ICI initiation. There was no difference in OS between the RA and non‐RA NSCLC Kaplan‐Meier survival curves (log‐rank P = 0.08) and in adjusted models (hazard ratio 0.92, 95% confidence interval 0.78–1.09). Male sex, having more comorbidities, and steroid dose before ICI initiation were associated with worse OS. In a sensitivity analysis omitting patients receiving baseline dexamethasone, steroid dose before ICI initiation was no longer associated with worse OS.
Conclusion
After controlling for demographics and comorbid conditions, ICI‐treated patients with RA with mNSCLC had no difference in OS compared with patients without RA. After excluding patients receiving dexamethasone, steroid dose was not associated with worse OS. image
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Hospital for Special Surgery, New York, New York.
- Weill Cornell Medicine, New York, New York.
- University of Alabama at Birmingham.
ORCID-Profile: Deanna P Jannat-Khah, Jeffrey R Curtis, Anne R Bass
Förderung
- NIAMS NIH HHS
- Hospital for Special Surgery
- National Institute of Arthritis and Musculoskeletal and Skin Diseases
Zitieren
APA
Jannat-Khah, D. P., Xie, F., Saxena, A., Curtis, J. R., & Bass, A. R. (2025). Survival in Immune Checkpoint Inhibitor–Treated Patients With Rheumatoid Arthritis and Non–Small Cell Lung Cancer: An Observational Cohort Study. Arthritis Care & Research. https://doi.org/10.1002/acr.25561
Vancouver
Jannat-Khah DP, Xie F, Saxena A, Curtis JR, Bass AR. Survival in Immune Checkpoint Inhibitor–Treated Patients With Rheumatoid Arthritis and Non–Small Cell Lung Cancer: An Observational Cohort Study. Arthritis Care & Research. 2025. doi:10.1002/acr.25561
BibTeX
@article{JannatKhah2025,
author = {Jannat-Khah, Deanna P and Xie, Fenglong and Saxena, Ashish and Curtis, Jeffrey R and Bass, Anne R},
title = {Survival in Immune Checkpoint Inhibitor–Treated Patients With Rheumatoid Arthritis and Non–Small Cell Lung Cancer: An Observational Cohort Study},
journal = {Arthritis Care & Research},
year = {2025},
doi = {10.1002/acr.25561}
}
EUVIMED